Source - SMW
Midatech Pharma said US subsidiary Midatech Pharma US has finalised a co-promotion agreement with R-Pharm US LLC providing additional reach and frequency for the promotion of Zuplenz and Oravig to oncology accounts across the US.

Under the terms of the agreement, R-Pharm will promote Zuplenz and Oravig in accounts that are not currently in the Midatech Pharma US call universe as well as provide additional promotion in accounts where Midatech currently markets its oncology supportive care product portfolio.

Related Charts

Midatech Pharma (MTPH)

0.00p (0.00%)
delayed 18:15PM